Effects of Diane-35 on the glucose and lipid metabolism in patients with polycystic ovary syndrome

doi:10.3969/j.issn.1006-7795.2016.04.003

Abstract

Abstract: Objective To observe the effects of Diane-35 on polycystic ovary syndrome (PCOS), and to investigate its influence on hormone, glucose and lipid metabolism in PCOS patients. Methods Totally 100 patients diagnosed as PCOS were divided into two groups, metabolic syndrome (MS) group (n=64) and non-MS group (n=36), according to the MS criteria formulated by International Diabetes Federation (IDF). Hormone level and parameters of glucose and lipid metabolism were detected and compared between the two groups before and after treatment by Diane-35 for 3 months. Results The body mass index decreased significantly after treatment in MS group, while no obvious change in non-MS group. The serum testosterone and LH/FSH decreased in both groups (P<0.05). The total cholesterol in MS group slightly decreased, but increased significantly in non-MS group. The triglyceride in both groups increased significantly, especially in MS group, and the difference between the groups was statistically significant. HDL-C increased in both group, but only increased significantly in non-MS group (P<0.05). LDL-C decreased in MS group and increased in non-MS group without statistical difference, but the difference of between the groups was statistically significant. Fasting glucose decreased in MS group and increased in non-MS group significantly, and the difference between the groups was statistically significant. Fasting insulin decreased in MS group and increased in non-MS group without significant difference, and the difference between the groups was not significant. Conclusion Diane-35 can modify the menstrual cycle, and improve the hyperandrogenism such as hirsutism and acne, and do not deteriorate the glucose and lipid metabolism. PCOS treatment should combine diane-35 with diet and exercise, helping PCOS patients achieving the best effect.

Key words: polycystic ovary syndrome, metabolic syndrome, Diane-35, glucose and lipid metabolism

CLC Number:

R711.75

Li Yanglu, Ruan Xiangyan, Zhao Yue, Du Juan, Wang Lijuan, Cui Yamei, Alfred O. Mueck. Effects of Diane-35 on the glucose and lipid metabolism in patients with polycystic ovary syndrome[J]. Journal of Capital Medical University, 2016, 37(4): 424-430.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2016.04.003

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2016/V37/I4/424

References

[1] Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome(PCOS)[J]. Hum Reprod, 2004, 19(1): 41-47.
[2] Alberti K G, Zimmet P, Shaw J. et al. The metabolic syndrome-a new worldwide definition[J]. Lancet, 2005, 366(9491): 1059-1062.
[3] Alberti KGMM, Eckel R H, Grundy S M, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity[J]. Circulation, 2009, 120(16): 1640-1645.
[4] Bil E, Dilbaz B, Cirik D A. Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype[J]. J Obstet Gynaecol Res, 2016,42(7):837-843.
[5] Kelly C C, Lyall H, Petrie JR, e t al. Low grade chronic inflammation in women with polycystic ovarian syndrome[J]. J Clin Endocrinol Metab, 2001,86(6):2453-2435.
[6] Gallo M F, Lopez L M, Grimes D A, et al. Combination contraceptives: effects on weight[J]. Cochrane Database Syst Rev, 2014, 29(1):CD003987.
[7] Orbetsova M, Kamenov Z, Kolarov G, et al. Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy[J]. Akush Gimekol: sotilia, 2006,45(7):16-28.
[8] Wu H, Ruan X, Jin J, et al. Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes[J]. Gynecol Endocrinol, 2015, 31(7):548-551.
[9] Trikudanathan S. Polycystic ovarian syndrome[J]. Med Clin North Am, 2015, 99(1):221-235.
[10] Hsu M I, Liou T H, Liang S J, et al. Inappropriate gonadotropin secretion in polycystic ovary syndrome[J]. Fertil Steril, 2009, 91(4):1168-1174.
[11] 马从顺,林芸,张春晖,等. 血清黄体生成素与卵泡刺激素比值对卵巢多囊样改变患者确诊多囊卵巢综合征的价值[J]. 中华妇产科杂志, 2011, 49(3): 177-181.
[12] Wu J, Zhu Y, Jiang Y, et al. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome[J]. Gynecol Endocrinol, 2008, 24(7):392-398.
[13] 陈雪梅. 不同药物预处理多囊卵巢综合征并不孕患者的疗效及副反应分析[J]. 实用医学杂志, 2011,27 (15): 2830-2832.
[14] Ehrmann D A. Polycystic ovary syndrome[J]. N Engl J Med, 2005, 352(12):1223-1236.
[15] Cagnacci A, Paoletti A M, Renzi A, et al. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel[J]. J Clin Endocrinol Metab, 2003,88(8):3621-3625.
[16] Vrbíková J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome[J]. Hum Reprod Update, 2005,11(3):277-291.
[17] Halperin I J, Kumar S S, Stroup D F. The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies[J]. Hum Reprod, 2011, 26(1):191-201.
[18] Karabulut A, Demirlenk S, Sevket O. Effects of ethinyl estradiol-cyproterone acetate treatment on metabolic syndrome, fat distribution and carotid intima media thickness in polycystic ovary syndrome[J]. Gynecol Endocrinol, 2012,28(4):245-248.
[19] Jing Z, Liang-Zhi X, Tai-Xiang W, et al. The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: An updated systematic review[J]. Gynecol Endocrinol, 2008, 24(10):590-600.
[20] 武红琴,阮祥燕,卢永军,等. 综合管理下达英-35与达英-35联合二甲双胍治疗多囊卵巢综合征的疗效研究[J]. 首都医科大学学报, 2014,35(4):407-413.
[21] 卢永军,阮祥燕,田玄玄,等. 多囊卵巢综合征综合治疗疗效的评价[J]. 首都医科大学学报,2013,34(4):525-529.
[22] 杨颖,王金敏,彭书苹,等. 肥胖型多囊卵巢综合征患者临床特征分析[J]. 中国煤炭工业医学杂志, 2014,17(9) :1453-1455.